Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device company developing the IzoView dedicated breast CT imaging system, has announced its intention to complete a non-brokered private placement with a strategic investor. The offering consists of 750,000 units priced at $0.20 each, targeting gross proceeds of up to $150,000. The funds are earmarked for general working capital as the company continues its commercialisation efforts. Completion remains subject to regulatory approvals and standard closing conditions.

Key Points

  • Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3)
  • The company intends to raise up to $150,000 through a non-brokered private placement of 750,000 units at $0.20 per unit with a single strategic investor
  • Each unit includes one common share and one warrant exercisable at $0.30 per share for three years from closing
  • Investors may be watching for regulatory approval confirmations and the formal closing of the offering

Offering Structure and Warrant Terms for Izotropic's Private Placement

Under the terms announced, each of the 750,000 units is priced at $0.20 and comprises one common share and one transferable warrant. Each warrant entitles the holder to acquire one additional common share at $0.30 for a period of three years from the closing date of the offering. All securities issued will be subject to a statutory hold period of four months and one day from the date of issuance, in accordance with applicable Canadian securities legislation. The offering is non-brokered and directed at a single strategic investor, the identity of whom was not disclosed in the announcement.

Use of Proceeds and Regulatory Conditions

Izotropic has stated that proceeds from the offering will be applied entirely to general working capital. The company did not disclose specific allocations within that category. Completion of the offering is conditional upon receipt of all necessary regulatory approvals, among other standard closing conditions. The securities have not been and will not be registered under the United States Securities Act of 1933, and the announcement explicitly states they may not be offered or sold in the United States without registration or an applicable exemption.

IzoView Breast CT System Commercialisation Context

Izotropic describes itself as a medical device company focused on commercialising IzoView, a dedicated breast CT imaging system designed for more accurate breast cancer screening and diagnosis. The company's announcement notes that IzoView has not yet been approved or cleared for sale. The private placement, while modest in size, reflects ongoing efforts to maintain the working capital necessary to advance the device toward commercialisation. The immediate share price impact was not clear from available public information.